Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE

Aphex BioCleanse (SNST) Making Serious Headlines.

Relatively quiet for most of the year. Aphex BioCleanse, our favorite Super Bug sanitizer company, made two back-to-back announcements - signaling things...
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
Biotech Stock Review. Citius, CTXR

More Great News From Citius Pharma (CTXR).

UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Auris Medical, Altamira Therapeutics

Adding Auris Medical (EARS) $3.50 to Biotech Watch List.

Auris Medical soared 590% in one Week on Covid Related News on December 1st, 2020. LIFT OFF...
Aphex Biocleanse Systems

Aphex BioCleanse Further Expands Distribution Channels.

Aphex BioCleanse Systems Announces Partnership With Bifulco Consulting Group to Expand Distribution Channels PITTSFORD, N.Y., May 20, 2021...

Citius Pharma (CTXR) Updates Shareholders.

Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Dermaphex

Aphex BioCleanse System’s (SNST) Significant Hand Sanitizer Purchase Order.

Aphex BioCleanse Systems Announces Significant Purchase Order for Proprietary, Alcohol-Free Hand Sanitizer Product PITTSFORD, N.Y. , May 4, 2021 /PRNewswire/ -- Aphex...

Stem Cell Play Organicell (BPSR) Screams Higher.

Stock Levitates After Series of Positive Press Releases on Zofrin. Added to the Watch List in April a...
Citius, Leonard Mazur

Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS

Latest article

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...